Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

LEXICON PHARMACEUTICALS, INC.

(LXRX)
My previous session
Most popular
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Lexicon Pharmaceuticals, Inc. : Lexicon Pharma to cut 45 percent jobs, CEO to leave

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2014 | 06:57am EST

(Reuters) - Lexicon Pharmaceuticals Inc said its Chief Executive would leave and it would cut its workforce by about 45 percent, as it moves its focus away from drug discovery to completing the studies of its drugs in late-stage development.

Lexicon said it would cut 115 jobs, primarily positions in research and discovery to reduce costs.

"This transition increases Lexicon's financial strength and will enable the company to more effectively advance our key late-stage programs and to prepare for commercialization," CEO Arthur Sands said in a statement on Monday.

The company said it would focus mainly on its drugs to treat diabetes and carcinoid syndrome, a condition which affects some people with a rare cancerous tumor.

Lexicon said it expects to lower expenses by about $14 million, net of severance costs and some other charges, for the rest of 2014. It expects to save about $22 million annually.

The company had $151.2 million in cash and investments as of September 30 last year.

The company said Sands intends to develop a succession plan with the board to identify a new CEO, and will continue in his position until a successor is appointed.

The company is testing two other drugs in mid-stage trials to treat irritable bowel syndrome and rheumatoid arthritis. It also has a glaucoma drug in early-stage development.

Lexicon said last month its irritable bowel syndrome drug did not meet the main goal of a mid-stage study.

Lexicon shares, which lost about 15 percent of their value last year, closed at $2 on the Nasdaq on Friday.

(Reporting by Vrinda Manocha in Bangalore; Editing by Joyjeet Das)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LEXICON PHARMACEUTICALS, I
02/08LEXICON PHARMACEUTICALS : RM LAW Announces Class Action Lawsuit Against Lexicon ..
PR
01/30LEXICON Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedi..
PR
01/30ROBBINS ARROYO LLP : Lexicon Pharmaceuticals, Inc. (LXRX) Misled Shareholders Ac..
BU
01/29FEDERMAN & SHERWOOD : Announces Filing of Securities Class Action Lawsuit Agains..
BU
01/18LEXICON PHARMACEUTICALS : Stock Trading Halted Today, FDA Advisory Committee to ..
AQ
01/18LEXICON PHARMACEUTICALS : Stock Trading Halted Today; FDA Advisory Committee to ..
AQ
01/17Sanofi/Lexicon Diabetes Drug Gets 8-8 Vote From FDA Panel -- Update
DJ
01/17Sanofi/Lexicon Diabetes Drug Gets 8-8 Vote From FDA Panel
DJ
01/17LEXICON PHARMACEUTICALS : FDA Advisory Committee Votes on Zynquistatm (Sotaglifl..
PU
01/17FDA Advisory Committee Votes on Zynquista™ (sotagliflozin) as Treatment..
GL
More news
Financials ($)
Sales 2018 59,3 M
EBIT 2018 -117 M
Net income 2018 -130 M
Debt 2018 145 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 11,9x
EV / Sales 2019 4,49x
Capitalization 562 M
Chart LEXICON PHARMACEUTICALS, INC.
Duration : Period :
Lexicon Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 21,3 $
Spread / Average Target 302%
EPS Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & Executive Vice President
Frank P. Palantoni Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICALS, INC.12.10%562
GILEAD SCIENCES6.73%86 362
VERTEX PHARMACEUTICALS13.49%47 772
REGENERON PHARMACEUTICALS13.51%45 158
SAREPTA THERAPEUTICS INC28.81%9 373
GENMAB-7.26%9 252